NO924940L - Polycykliske guaninderivater - Google Patents

Polycykliske guaninderivater

Info

Publication number
NO924940L
NO924940L NO92924940A NO924940A NO924940L NO 924940 L NO924940 L NO 924940L NO 92924940 A NO92924940 A NO 92924940A NO 924940 A NO924940 A NO 924940A NO 924940 L NO924940 L NO 924940L
Authority
NO
Norway
Prior art keywords
aryl
alkyl
hydroxy
heteroaryl
carbon atoms
Prior art date
Application number
NO92924940A
Other languages
English (en)
Other versions
NO924940D0 (no
Inventor
Bernard R Neustadt
Neil A Lindo
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO924940L publication Critical patent/NO924940L/no
Publication of NO924940D0 publication Critical patent/NO924940D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Filtering Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Nye, polysykliske guanin- derivater av formel (I) og (I'), hvori ; J er oksygen eller svovel, R1 er hydro- . gen, alkyl eller alkyl substituert med aryl eller hydroksy; R3 er hydrogen, aryl, heteroaryl, cykloalkyl, alkyl eller alkyl substituert med aryl, hetero- aryl, hydroksy, alkoksy, amino, mono- alkylamino eller dialkylamino, eller -(CH2)mTCOR30 hvori m er et helt tall fra l til 6, T er oksygen eller -NH- og R20 er hydrogen, aryl, heteroaryl, alkyl eller alkyl substituert med aryl eller heteroaryl; R3 er hydrogen, halogen, trifluormetyl, alkoksy, alkyltio, alkyl, cykloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroksy- alkylamino, aminoalkylamino, karboksy, alkoksykarbonyl eller aminokarbonyl eller alkyl substituert med aryl, hydroksy, alkoksy, amino, monoalkylamino eller dialkylamino; R», Rto, R= og R* be- tegner uavhengig hydrogen, alkyl, cyklo- alkyl eller aryl; eller (R- og Rb) eller (R= og R*) eller (Rb og R=) kan fullføre en mettet ring på 5 til 7 karbonatomer, eller (R«* og Rto) tatt sammen og (Rto og R=) tatt sammen, hver fullfører en mettet ring på 5 til 7 karbonatomer, hvori hver ring eventuelt kan inneholde et svovel- eller oksygenatom og hvis karbonatomer eventuelt kan være substi- tuert med en eller flere av følgende: alkenyl, alkynyl, hydroksy, karboksy, alkoksykarbonyl, alkyl eller alkyl sub- stituert med hydroksy, karboksy eller alkoksykarbonyl; eller slik mettet ring kan ha to tilstøtende karbonatomer som deles med en tilstøtende arylring; og n er O eller l. Forbindelsene av formel (I) og (I') er anvendbare som antihyper- tensive midler, muskelrelakserende midler og bronkodilaterende midler.
NO924940A 1990-06-21 1992-12-18 Polycykliske guaninderivater NO924940D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
NO924940L true NO924940L (no) 1992-12-18
NO924940D0 NO924940D0 (no) 1992-12-18

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924940A NO924940D0 (no) 1990-06-21 1992-12-18 Polycykliske guaninderivater

Country Status (21)

Country Link
US (1) US5393755A (no)
EP (1) EP0538332B1 (no)
JP (1) JPH0747589B2 (no)
KR (1) KR960004532B1 (no)
AT (1) ATE155786T1 (no)
AU (1) AU651607B2 (no)
CA (1) CA2085733C (no)
CZ (1) CZ281920B6 (no)
DE (1) DE69126980T2 (no)
FI (1) FI925731A7 (no)
HU (1) HUT65623A (no)
IE (1) IE912126A1 (no)
IL (1) IL98559A0 (no)
NO (1) NO924940D0 (no)
NZ (1) NZ238609A (no)
OA (1) OA09723A (no)
PL (1) PL169481B1 (no)
RU (1) RU2080322C1 (no)
TW (1) TW197441B (no)
WO (1) WO1991019717A1 (no)
ZA (1) ZA914727B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686157A1 (en) * 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE602004006756T2 (de) * 2003-07-31 2008-01-24 Schering Corp. Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
AU2004260758B2 (en) * 2003-08-01 2007-06-07 Nippon Soda Co., Ltd. Phenylazole compounds, production process, and antioxidants
MXPA06005681A (es) * 2003-11-21 2006-08-17 Schering Corp Formulaciones de inhibidores de la fosfodiesterasa v.
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
WO2006133261A2 (en) * 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
BRPI0618482A2 (pt) * 2005-11-09 2011-08-30 Tosoh Corp nucleobase contendo grupo perfluoroaquila e processo para a produção da mesma
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US8349858B2 (en) 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
ES2588238T3 (es) * 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
PE20110922A1 (es) * 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
BRPI1009398A2 (pt) * 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives

Also Published As

Publication number Publication date
WO1991019717A1 (en) 1991-12-26
CZ281920B6 (cs) 1997-04-16
CA2085733A1 (en) 1991-12-22
FI925731A0 (fi) 1992-12-17
AU8199291A (en) 1992-01-07
NZ238609A (en) 1993-12-23
TW197441B (no) 1993-01-01
JPH0747589B2 (ja) 1995-05-24
DE69126980D1 (de) 1997-09-04
AU651607B2 (en) 1994-07-28
IL98559A0 (en) 1992-07-15
HU9204032D0 (en) 1993-03-29
NO924940D0 (no) 1992-12-18
KR960004532B1 (ko) 1996-04-06
OA09723A (en) 1993-08-30
JPH05508647A (ja) 1993-12-02
HUT65623A (en) 1994-07-28
CZ374992A3 (en) 1993-10-13
ZA914727B (en) 1992-03-25
RU2080322C1 (ru) 1997-05-27
DE69126980T2 (de) 1998-01-08
EP0538332A1 (en) 1993-04-28
CA2085733C (en) 1996-03-05
US5393755A (en) 1995-02-28
PL297299A1 (no) 1992-07-13
PL169481B1 (pl) 1996-07-31
ATE155786T1 (de) 1997-08-15
FI925731A7 (fi) 1992-12-17
IE912126A1 (en) 1992-01-01
EP0538332B1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
CA2085733A1 (en) Polycyclic guanine derivatives
BG102792A (bg) Производни на заместени 4-хидроксифенилалканоилови киселини с агонистична активност към рраr-гама
TR200002671T2 (tr) Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler
ATE338754T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DE69720773D1 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
DE69431576D1 (de) Isoxazole Derivate und ihre Verwendung als Herbizide
TW376385B (en) Watersoluble azole antifungals
DE3750111D1 (de) Substituierte Phenyl-2-propensäure Derivate und ihre Verwendung als Fungizide.
HUP0301387A2 (hu) Szintetikus módszerek aplidin és új tumorellenes származékok előállítására
ATE296300T1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
ES2110260T3 (es) Androstenonas.
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
MY138051A (en) Compounds and processes
AU7769587A (en) New compounds, processes for their preparation and their use
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
ES2126693T3 (es) Derivado de triazina, su produccion y su uso.
DK1021421T3 (da) Amino- og hydroxy-substituerede triphenyl-S-triaziner som stabilisatorer
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
DE69637283D1 (de) Analoge von n-acetylardeemin, verfahren zur herstellung und verwendung dieser analogen
MX9708552A (es) (het)ariloxi-, -tio- y -aminocrotonatos, su preparacion y uso.
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ATE300532T1 (de) Piperazinon-derivate
DE502004009016D1 (de) Verwendung von chinaldin-und naphthalinderivaten als kristallisationsmodifikatoren
ATE235822T1 (de) Verwendung von sulfonyloxadiazolonen als mikrobizide